AstraZeneca Falls On Downgrade In Rating

By Monica Gerson
Benzinga Staff Writer
September 29, 2010 6:10 AM

Symbols: AZN

Posted in: Analyst Color, Downgrades, Markets, Analyst Ratings

Shares of AstraZeneca Plc (NYSE: AZN) moved down in pre-market trading after Royal Bank of Scotland downgraded the company.

RBS downgraded AZN from “buy” to “hold.” The broker said, "AstraZeneca had a strong run of positive news flow over the summer and the near-term share price drivers have played out. AstraZeneca is within 10% of our target price and we lower our recommendation to hold."

AZN shares dropped 0.88% to $51.56 in pre-market trading.

More Analyst Ratings here

< Previous
Morgan Stanley Ups Rolls-Royce, Safran

Next >
Piper Jaffray Neutral On CryoLife (CRY)

Printer-friendly version

Send to friend

We're Loving

5 Value Stocks Insiders Are Snapping Up

Greece ETF Leads Market Down As Airlines Take Off

Apple’s ‘iTV’ Might Not Be a TV at All

You Could Have Profited 14% on AOL by Using Benzinga Pro. Try It for Free Now!

5 Bank Stocks Wilting Under the Summer Sun

Benzinga's Premium Memberships

Options & Volatility Edge

Options & Volatility Edge is for those people who want to make money using cost effective options trading strategies. This product is for anyone—novices and experts. If you understand how to enter an options trade, you need Options & Volatility Edge.

Learn More >>
14 Day Free Trial!

Basic Premium
ETF Professor

The ETF Professor is truly an appropriate moniker, because the Professor spends hours everyday analyzing the charts of dozens of ETFs EVERY DAY.

Learn More >>
14 Day Free Trial!

Basic Premium
Winning Stocks

Winning Stocks tracks and analyzes attractive stocks that are poised to make great returns for the average investor. Investors receive the right information at the right time, which provides them with the possibility for great gains and the potential to beat the market.

Learn More >>
14 Day Free Trial!

Basic Premium

Real-Time Rumors

In this game, information is everything. You have to know what is happening before the Street begins trading against you utilizing the new information. We will provide you with that edge.

Learn More >>
14 Day Free Trial!

Basic Premium
Chart-Caster

From novice to pro, Chart-Caster delivers over $11,000 per month* in profitable trade setups across all time-frames from which members can evaluate, select, and replicate within their own trading accounts.

Learn More >>
14 Day Free Trial!

Basic Premium

AstraZeneca Falls On Downgrade In Rating

Benzinga's Premium Memberships

More stories by Monica Gerson

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social